State College, Pennsylvania – Today the staff of INDIGO Biosciences, Inc. congratulates their own Prajakta Albrecht, PhD, for her recent DABT certification!
Online PR News – 16-December-2013 –State College, Pennsylvania – Today the staff of INDIGO Biosciences, Inc. congratulates their own Prajakta Albrecht, PhD, for her recent DABT certification!
Administered by the American Board of Toxicology, Inc., the DABT (Diplomate of American Board of Toxicology) certification establishes a globally recognized standard in toxicology. Attainment of the DABT Certification requires a wide, working knowledge of toxicology, as well as an understanding of its applications in related fields.
“The DABT Certification represents competence and commitment to human health and environmental sciences based on educational background and active practice of toxicology,” said Prajakta Albrecht, PhD.
Dr. Albrecht’s DABT certification is but the latest in an already-impressive list of professional accomplishments and credentials. Since her completion of a PhD in Toxicology from the University of Louisiana in 2008, Dr. Albrecht has served as a postdoctoral scholar at Pennsylvania State University and authored multiple research publications in the field of toxicology.
Dr. Albrecht brings her vast experience and knowledge to her role at INDIGO, where she has served as a scientist since 2011. According to Bruce A. Sherf, Ph.D., Chief Technology Officer at INDIGO Biosciences, “The DABT Certification demonstrates the depth of INDIGO’s knowledge in toxicology, with our special focus in nuclear receptors.”
Founded in 2005, privately-held INDIGO Biosciences, Inc. provides unique, cost-effective, reliable and user-friendly target-specific nuclear receptor assay products and contract screening services to drug developers, toxicologists and researchers within the pharmaceutical, biotechnology and chemical industries.
INDIGO Biosciences, Inc.
INDIGO Biosciences continues to provide high-quality, confidential screening services for drug discovery and active ingredient determination.
However, in 2008 The Company's mission changed dramatically. Instead of being strictly a service provider, INDIGO Biosciences is now dedicated to establishing itself as the premier provider of cell-based nuclear receptor reporter assay products.
The technology that enabled this transformation was The Company's development of a unique and superior processing method to cryo-preserve its nuclear receptor reporter cells. This proprietary process, called CryoMite™, provides long-term cryo-preservation of cells for shipping and storage, providing users the convenience of readily available robust cell-based reporter assays for on-demand use.